Loading patent…
AssigneeCentre National de la Recherche Scientifique - CNRS, a corporation of France
InventorsAnnick Harel-Bellan, Slimane Ait-Si-Ali, Florence Cabon-Georget, Anne Chauchereau, Francois Dautry, Luis Martinez
Estimating the term…
A double-strand oligonucleotide including two complementary oligonucleotide sequences forming a hybrid, each including at one of their 3′ or 5′ ends, one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid, one of the oligonucleotide sequences being substantially complementary to a target sequence belonging to a DNA or RNA molecule to be specifically repressed, the target sequence belonging to a DNA or RNA molecule of a gene coding an angiogenic factor.
A double-strand oligonucleotide comprising two complementary oligonucleotide sequences forming a hybrid, each comprising at one of their 3′ or 5′ ends, one to five unpaired nucleotides forming single-strand ends extending beyond the hybrid, one of the oligonucleotide sequences being substantially complementary to a target sequence belonging to a DNA or RNA molecule to be specifically repressed, the target sequence belonging to a DNA or RNA molecule of a gene coding an angiogenic factor.
Dependencies are inferred from the claim text.